ClinicalTrials.gg
Active, not recruitingNCT04900844C-GuardiansUpdated Apr 4, 2025

Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

An interventional study of CGuard Carotid Stent implantation in Carotid Artery Stenosis, sponsored by InspireMD. Active, not recruiting at 18 sites in 2 countries. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by InspireMD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
317
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.

Enrollment
12th of 53
317 · median 69
Started
2021
with 1 other
No phase
29 of 84
4 open now
Primary completion
2022-07
later than 1 of 12 live
Registered
75th of 84
by date
Lead sponsor
2 of 84
InspireMD

Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 12th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2021, is one of 29 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 75th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Carotid Stenosis with a site in United States, or all of them as a file.
02

Study summary

The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.

03

Conditions studied

  • Carotid Artery Stenosis

Keywords

  • Carotid Stenosis
  • Stenting
  • Prospective study
  • Embolic Protection Device (EPD)
  • Carotid Artery Diseases
  • Cerebrovascular Disorders
  • Constriction, Pathologic
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is willing and able to provide appropriate study-specific , follow protocol procedures, and comply with follow-up visit requirements.
  2. Subject is willing and able to take dual antiplatelet therapy for a minimum of 30 days.
  3. ≥ 24 months from the date of the index procedure.
  4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
  5. Subject has a modified Rankin Score of ≤ 2at the time of informed consent.
  6. Subject is diagnosed with carotid artery disease treatable with carotid artery stenting and is considered high risk for carotid endarterectomy (CEA) as evidenced by:

    1. Symptomatic carotid stenosis ≥ 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack () or stroke within the last 6 months ipsilateral to the side of the stenosis.

      Or

    2. Asymptomatic carotid stenosis ≥ 80%
  7. Co-Morbidity High Risk Conditions for CEA, i.e., meets one or more of the following criteria:

    1. Age ≥ 70 (maximum 80 years)
    2. CCS angina class 3-4 or unstable angina
    3. Congestive Heart Failure (CHF) class III-IV
    4. (LVEF) ≤ 35%
    5. MI ≥ 72 hours and \< 6 weeks pre-procedure
    6. Multi-vessel CAD (≥ 2 vessels >70% stenosis) and history of angina
    7. (COPD) with \<50
    8. Permanent contralateral cranial nerve injury/paralysis
    9. Restenosis from previous carotid endarterectomy (CEA)
    10. Planned coronary artery bypass grafting (CABG) or valve replacement surgery between 31-60 days after CAS
    11. Abdominal aortic aneurysm repair or peripheral vascular surgery is planned between 31 to 60 days after CAS.

    OR

  8. High Anatomical Risk for CEA, i.e., meets one or more of the following criteria:

    1. Occlusion of the contralateral CCA or ICA.
    2. Prior radiation treatment to the neck or a radical neck dissection.
    3. Severe bilateral ICA stenosis requiring treatment.
    4. Target lesion at or above the level of the jaw (C2) or below the clavicle.
    5. Severe tandem lesions
    6. Inability to extend the hear due to cervical disorders.
    7. Laryngeal palsy or laryngectomy.
    8. Prior head and neck surgery in the region of the carotid artery.
    9. Tracheostomy or tracheostoma.
    10. Spinal immobility of the neck.
    11. Hostile neck or surgically inaccessible lesion.

10. Angiographic General Inclusion Criteria, i.e., meets all the following criteria:

  1. Target lesion location at the carotid bifurcation and/or proximal internal carotid artery (ICA)
  2. Vessel distal to target lesion can accommodate a distal embolic protection device (EPD), and EPD is compatible with CGuard™ device (refer to CGuard™ System IFU for specific EPDs).
  3. Target vessel reference diameter at stent landing zone is 4.8 mm to 9.0 mm.
  4. Target lesion length ≤ 36 mm, that can be covered by a single CGuard™ stent.

Exclusion criteria

Exclusion Criteria:

  1. Planned interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index carotid procedure.
  2. Severe vascular anatomy that would preclude safe sheath insertion, deliverability of stent or embolic protection device.
  3. Type III or bovine aortic arch.
  4. Total occlusion of the target vessel.
  5. Presence of "String sign" of the target lesion.
  6. In-tandem lesions with >= 50% or >= 80% diameter stenosis for symptomatic or asymptomatic patients, respectively, which cannot be covered by a single CGuard™ stent.
  7. History of bleeding diatheses or coagulopathy or inability to accept blood transfusions.
  8. Bilateral carotid stenosis requiring treatment on both sides within 30 days prior to or following planned index procedure.
  9. Subject is on renal replacement therapy or has Stage 4 or 5 Chronic Kidney Disease (CKD).
  10. Known reason for potential stroke other than carotid artery stenosis, including history of atrial fibrillation or other sources of thromboemboli within the past 12 months.
  11. History of thrombophilia.
  12. Known sensitivity or allergy to nitinol, titanium, heparin, aspirin or other anticoagulant/ antiplatelet therapies.
  13. Contrast media sensitivity or allergy that cannot be pre-treated.
  14. Previous stent placement in the target vessel.
  15. Evolving stroke or intracranial hemorrhage, or history of previous intracranial hemorrhage or brain surgery within the past 12 months.
  16. Major neurologic deficit with NIHSS of ≥ 15.
  17. Dementia or other neurologic condition confounding the neurologic assessment.
  18. Clinical condition that, in the opinion of the investigator, makes endovascular therapy impossible or hazardous.
  19. Subject previously enrolled in this clinical trial.
  20. Possible / probable non-compliance of subject with protocol required follow up or medication.
  21. Subject is currently participating in another clinical trial that has not completed its primary endpoint assessment or would confound this C-GUARDIANS Pivotal IDE Clinical Study.
  22. SARS-CoV2 (COVID-19) active infection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    CGuard group

    Single experimental arm compared vs. objective performace goal

    Device: CGuard Carotid Stent implantation

Interventions

  • DeviceCGuard Carotid Stent implantation

    Implantation of CGuard carotid stent in the eligible patients

    Also known as: Carotid stenting

06

What researchers measure

Primary outcomes

  1. Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure

    The primary endpoint is the composite of the following: * Incidence of the following Major Adverse Events: Death (allcause mortality), all Stroke, and Myocardial Infarction (DSMI) through 30-days post-index procedure, based on Clinical Events Committee (CEC) adjudication OR * Ipsilateral stroke from 31-365 day follow-up, based on Clinical Events Committee (CEC) adjudication.

    Time frame: From index procedure to 1 year follow up

Secondary outcomes

  1. Incidence of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years

    Incidence of the following composite of Major Adverse Events: Death (all-cause mortality), all Stroke, and Myocardial Infarction (DSMI) through discharge, 30-days, 6-months, and 1-,2-,3-year follow-up, based on Clinical Events Committee (CEC) adjudication.

    Time frame: From index procedure to 3 years follow up

  2. Incidence of particular components of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years

    Incidence of each individual component of the Major Adverse Events: Death (all-cause mortality), all Stroke, and Myocardial Infarction (DSMI) through discharge, 30-days, 6-months, and 1-,2-,3-year follow-up, based on Clinical Events Committee (CEC) adjudication.

    Time frame: From index procedure to 3 years follow up

  3. Incidence of ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.

    Ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.

    Time frame: From index procedure to 3 years follow up

  4. Incidence of major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.

    Major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.

    Time frame: From index procedure to 3 years follow up

  5. Incidence of In-stent Restenosis (ISR) > 70% in ultrasound evaluation

    Incidence of In-stent Restenosis (ISR) \> 70%. ISR \> 70% is defined as PSV \> 300 cm/s associated with stent, or vessel occlusion based on transcervical duplex ultrasound through 1-, 2-, 3-year follow-up. Based on Imaging Core Laboratory assessment.

    Time frame: At 1-, 2-, 3-year post-index procedure follow-up

  6. Incidence of In-stent Restenosis (ISR) > 50% in ultrasound evaluation

    Incidence of In-stent Restenosis (ISR) \> 50%. ISR \> 50% is defined as PSV \> 220 cm/s associated with stent, or vessel occlusion based on transcervical duplex ultrasound through 1-, 2-, 3-year follow-up. Based on Imaging Core Laboratory assessment.

    Time frame: At 1-, 2-, 3-year post-index procedure follow-up

  7. Incidence of target lesion revascularization

    Incidence of Target Lesion Revascularization (TLR) through 1-,2,3-year follow-up. TLR is defined as clinically driven revascularization procedure of the original treatment site, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase the luminal diameter within the stented lesion or within 5 mm proximal or distal to the index stent.

    Time frame: At 1-, 2-, 3-year post-index procedure follow-up

  8. Composite of Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events

    Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events from discharge up to 1-,2- and 3-year follow-up.

    Time frame: From index procedure to 3 years follow up

  9. Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure for subjects that adhere to antiplatelet pharmacology.

    Primary endpoint for subjects that adhere to antiplatelet pharmacology.

    Time frame: From index procedure to 1 year follow up

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2022, 12 months.

Of 62 interventional studies with no phase under Carotid Stenosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2021
First posted
May 25, 2021
StartActual
Jul 1, 2021
Primary completionActual
Jul 1, 2022
CompletionEst.
Oct 1, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04900844
Lead sponsor
InspireMD
Responsible party
Sponsor
First posted
May 25, 2021
Start date
Jul 1, 2021
Primary completion
Jul 1, 2022
Completion
Oct 1, 2025 (estimated)
Last update
Apr 4, 2025

Study contacts

Chris Metzger, MD
principal investigator · Ballad Health
Piotr Musialek, MD DPhil
principal investigator · John Paul II Hospital, Krakow, Poland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion